GRWD5769 + cemiplimab

GRWD5769 + cemiplimab is an investigational combination therapy consisting of GRWD5769, an oral, potent, and selective first-in-class ERAP1 inhibitor developed by Grey Wolf Therapeutics, and cemiplimab, a fully human monoclonal antibody targeting programmed death receptor-1 (PD-1), marketed as Libtayo. GRWD5769 modulates the tumor immunopeptidome by inhibiting ERAP1, leading to the presentation of novel neoantigens and enhancing anti-tumor T cell responses, thereby circumventing T cell exhaustion, a key resistance mechanism in immuno-oncology[1][3][5]. Cemiplimab blocks PD-1, enhancing T cell-mediated anti-tumor activity. The combination aims to boost anti-tumor immunity beyond what either agent can achieve alone and is currently in early-phase clinical testing for advanced solid tumors[1][5].

Other names

GRWD5769 + Libtayo